Insider buying last 90 days
No open-market insider purchases were filed for PNTG in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PNTG insider filing, plotted on the chart in Gekko.Open PNTG in Gekko
NASDAQ: PNTG
Pennant (PNTG) Stock Analysis & Forecast
Oct 12 close
$40.52+0.79 (+2.0%)
Gekko Brief
AI summaryOct 12 closePennant (PNTG) draws attention this week on strong second-quarter results and a string of analyst actions. The company reported Q2 2026 revenue of $297.98 million, above consensus of $288.71 million, with adjusted EPS of $0.36 versus a $0.33 estimate. RBC raised its price target to $44.00 from $42.00, Jefferies also raised its target, and Pennant Group is set to meet with Oppenheimer on 13 October 2026. Eight analysts have maintained a Moderate Buy rating with an average target of $41.60 in one report, while the consensus among 4 firms tracked shows all 4 at buy with a target of $46.83.
PNTG closed at $40.52, up 2%, sitting above both its 50-day average of $39.23 and 200-day average of $34.53, with the shorter average above the longer one. The GekkoIndex reads 55.6, placing the stock in the Neutral zone. Gekko Fair Value stands at $42.27, putting price 4.1% below that level.
Over the next 20 trading days, Pennant is scheduled to report earnings on 4 November 2026, 22 days out, which falls inside a typical 20-day holding window. No insider, Congress or unusual options activity appears in the current window. Seasonally, the next 20 trading days from this point in the calendar have averaged a 7.1% return over 5 years, with gains in 4 of those years, a pattern worth noting alongside the upcoming earnings date.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Pennant price vs fair value
Close $40.52200-day averageGekko Fair Value $42.27
Pennant quick facts
- Market cap
- $1.41B
- P/E ratio
- 44.4
- Forward P/E
- 25.5
- EPS, TTM
- $0.91
- Revenue, TTM
- $1.10B
- Profit margin
- 2.9%
- Dividend yield
- —
- Beta
- 1.25
- Volume
- 205,823 avg 422,285
- 1-year return
- +61.8%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±8.2%
- 50-day average
- $39.23
- 200-day average
- $34.53
- Next earnings
- Nov 4
- Shares outstanding
- 34.93M
Pennant swing-trade checklist
Pennant scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $40.52 is above the 50-day ($39.23) and 200-day ($34.53) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.6, Neutral
Reading 55.6 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
4.1% below
Price is within 5% of Gekko Fair Value (4.1% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.1% on average
From this point in the calendar, the next 20 trading days averaged +7.1% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Pennant stock chart and price history
Pennant closed at $40.52 on Oct 12, 2026, +61.8% over the past year, inside a 52-week range of $22.26 to $42.74.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.4%
- 3 months
- +1.9%
- 6 months
- +29.4%
- 1 year
- +61.8%
The full PNTG chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PNTG in Gekko
Follow Pennant through every session
Put PNTG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PNTG in GekkoFree for 7 days. No credit card required.
About Pennant
Pennant works in healthcare, bringing patients and seniors a mix of home-based clinical care and residential senior living support. Its home health teams provide nursing, physical, speech and occupational therapy along with social work and aide services for patients in their own homes, while its hospice offering centers on clinical care, counseling and education for terminally ill patients and their families. Alongside these, the company runs senior living communities offering housing, meals, housekeeping and daily assistance for residents who live independently or need extra support.
The business is structured around two main divisions, Home Health and Hospice Services, and Senior Living Services, each addressing a different stage of patient or resident need. Through these segments Pennant serves individuals requiring in-home medical care, families seeking end-of-life support, and seniors looking for residential living arrangements. Its operations span a network of home health and hospice agencies together with a number of senior living communities spread across several western and midwestern states.
Pennant was founded in 2019 and is headquartered in Eagle, Idaho. Its shares trade on the NASDAQ under the ticker PNTG.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- pennantgroup.com
Pennant GekkoIndex: the smart money zone
Pennant’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.6, in the Neutral zone, up 0.2 points over five sessions.
55.6Neutral
Up 0.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | −0.1% | +5.4% | ||
| Accumulation | 155 | +1.0% | +2.5% | ||
| Neutral (current zone) | 441 | +0.7% | +3.4% | ||
| Distribution | 56 | +1.8% | +5.2% | ||
| Selling | 7 | Too few readings yet | |||
Average PNTG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PNTG price, zone by zone.Track PNTG in Gekko
Is Pennant stock overvalued? Gekko Fair Value
Pennant trades 4.1% below Gekko Fair Value of $42.27, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Pennant shares are worth, recalculated every trading day.
$42.27
Gekko Fair Value, Oct 10, 2026
4.1% below fair value · About fair value
At the end of Aug 2026 the price was 16.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PNTG in Gekko
Pennant insider and Congress trading
No open-market insider purchases were filed for Pennant, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PNTG were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PNTG, plotted on the chart in Gekko.Open PNTG in Gekko
Buybacks
Pennant has been buying back its own shares.
- Bought back, year ended Dec 31, 2020
- $65K
- As a share of market cap
- 0.00%
From company filings.
Pennant earnings: next date and track record
Pennant reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- $0.36
- Revenue estimate
- $299.3M
6 of 8reports beat the EPS estimate
±2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 26, 2026 AI summary
- What they said
- PNTG reported exceptional 2025 results with Q4 adjusted EPS of $0.34 and full-year adjusted EPS of $1.18, exceeding guidance midpoint of $1.16. Full-year revenue increased 36.3% to $947.7 million, while adjusted EBITDA grew 36% to $72.5 million. The company completed significant acquisitions including Signature Healthcare at Home and over 50 locations from UnitedHealth/Amedisys, while driving same-store improvements across segments.
- Guidance
- Following a year of tremendous growth, management is now intensely focused on optimizing performance and driving operational excellence. While remaining open to selective and opportunistic acquisitions, the primary focus shifts to operational improvements.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 26, 2026 | $0.34 est $0.32 | $289.3M est $275.2M | +1.9% |
| Nov 10, 2025 | $0.30 est $0.30 | — | −1.1% |
| Aug 6, 2025 | $0.27 est $0.27 | $219.5M est $214.6M | +8.7% |
| May 5, 2025 | $0.27 est $0.24 | $209.8M est $201.5M | +0.6% |
| Feb 26, 2025 | $0.24 est $0.24 | $188.9M est $185.8M | −0.9% |
| Nov 6, 2024 | $0.26 est $0.23 | $180.7M est $186.0M | +0.6% |
| Aug 6, 2024 | $0.24 est $0.22 | $168.7M est $156.8M | +0.2% |
| May 6, 2024 | $0.20 est $0.17 | $156.9M est $156.9M | −2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Pennant stock forecast and analyst price targets
Analysts’ average 12-month price target for Pennant is $46.83, +15.6% from the last close, from 4 firms rating the stock in the last 90 days.
$46.83consensus 12-month target, +15.6% from the last close
Now $40.52Avg $46.83
Low $44High $48
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Truist Financial | $48 | +18.5% |
| Aug 19 | RBC Capital | $44 | +8.6% |
| Aug 10 | Wells Fargo | $46 | +13.5% |
| Aug 7 | Truist Financial | $48 | +18.5% |
| Aug 6 | Truist Financial | — | — |
+3.4%average 20-day move after past Neutral readings
+7.1%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Pennant seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Pennant averaged +7.1% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 2 of 5 |
| Next 10 trading days | +1.7% | 4 of 5 |
| Next 15 trading days | +5.2% | 3 of 5 |
| Next 20 trading days | +7.1% | 4 of 5 |
| Next 30 trading days | +1.9% | 2 of 5 |
For scale, PNTG’s typical 20-trading-day move in either direction is about 8.2%.
Pennant market cap and key statistics
Pennant’s market cap is $1.41B, with a P/E ratio of 44.4 and revenue of $1.10B over the last twelve months.
Valuation
- Market cap
- $1.41B
- P/E ratio
- 44.4
- Forward P/E
- 25.5
- EPS, TTM
- $0.91
- Gekko Fair Value
- $42.27
Trading
- Volume
- 205,823
- Avg volume, 20 days
- 422,285
- 52-week high
- $42.74
- 52-week low
- $22.26
- Shares outstanding
- 34.93M
Financials
- Revenue, TTM
- $1.10B
- Profit margin
- 2.9%
- Return on equity
- 10.4%
- Quarterly earnings growth, YoY
- +25.0%
Risk and income
- Beta
- 1.25
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±8.2%
Pennant stock news this week
Coverage of Pennant this week reads positive: 4 positive, 0 neutral and 0 negative headlines.
- Pennant Group plans Oppenheimer meeting. RBC targets Pennant Group stock at USD 44.00AD HOC NEWS, Oct 8
- Pennant Group stock posts Q2 revenue above consensusAD HOC NEWS, Oct 7
- The Pennant Group, Inc. : Jefferies Raises TaMoomoo, Oct 6
- The Pennant Group stock gained 1.16 percent on October 2AD HOC NEWS, Oct 5
Pennant peers
Pennant’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Pennant stock FAQ
What is Pennant’s market cap?
Pennant’s market cap is $1.41B at the Oct 12, 2026 close of $40.52, with 34.93M shares outstanding. The shares trade on a P/E ratio of 44.4.
What is the Pennant stock forecast?
The consensus analyst 12-month price target for Pennant is $46.83, +15.6% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Pennant stock overvalued or undervalued?
On Gekko’s estimate Pennant is about fair value: the Oct 12, 2026 close of $40.52 is 4.1% below Gekko Fair Value of $42.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Pennant report earnings next?
Pennant is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of $0.36 per share on revenue of $299.3M. Pennant beat the earnings estimate in 6 of its last 8 reports, moving 2% on average across the report.
What is Pennant’s 52-week high and low?
Pennant’s 52-week high is $42.74 and its 52-week low is $22.26; it closed at $40.52 on Oct 12, 2026, +61.8% over the past year.
Is Pennant stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Pennant the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.